- Home
- STTK vs FINW Comparison
STTK vs FINW Comparison
Compare STTK & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FINW
- Stock Information
- Founded
- STTK 2016
- FINW 1999
- Country
- STTK United States
- FINW United States
- Employees
- STTK N/A
- FINW N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- STTK Health Care
- FINW Finance
- Exchange
- STTK Nasdaq
- FINW Nasdaq
- Market Cap
- STTK 56.8M
- FINW 212.8M
- IPO Year
- STTK 2020
- FINW 2021
- Fundamental
- Price
- STTK $1.12
- FINW $15.33
- Analyst Decision
- STTK Hold
- FINW Buy
- Analyst Count
- STTK 3
- FINW 3
- Target Price
- STTK $2.00
- FINW $18.67
- AVG Volume (30 Days)
- STTK 182.2K
- FINW 19.3K
- Earning Date
- STTK 02-27-2025
- FINW 01-30-2025
- Dividend Yield
- STTK N/A
- FINW N/A
- EPS Growth
- STTK N/A
- FINW N/A
- EPS
- STTK N/A
- FINW 1.06
- Revenue
- STTK $6,435,000.00
- FINW $69,509,000.00
- Revenue This Year
- STTK $313.04
- FINW N/A
- Revenue Next Year
- STTK N/A
- FINW $10.13
- P/E Ratio
- STTK N/A
- FINW $14.71
- Revenue Growth
- STTK 382.75
- FINW 4.87
- 52 Week Low
- STTK $0.94
- FINW $8.72
- 52 Week High
- STTK $11.76
- FINW $20.50
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- FINW 35.07
- Support Level
- STTK $1.13
- FINW $15.51
- Resistance Level
- STTK $1.39
- FINW $16.65
- Average True Range (ATR)
- STTK 0.11
- FINW 0.71
- MACD
- STTK 0.00
- FINW -0.07
- Stochastic Oscillator
- STTK 18.18
- FINW 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.